Biomerica shares surge 13.92% premarket as CMS sets $300 Medicare payment rate for inFoods IBS test.

Biomerica Inc. surged 13.92% in premarket trading following the announcement that the Centers for Medicare & Medicaid Services (CMS) established a $300 national payment rate for its inFoods® IBS test under the Clinical Laboratory Fee Schedule. This rate, effective January 1, 2026, provides clarity for Medicare claims and serves as a benchmark for private insurer negotiations, as CMS accounts for 21% of U.S. healthcare spending. The milestone follows the American Medical Association’s approval of a CPT code for the test, enhancing its commercial viability. The test addresses a significant unmet need in diagnosing irritable bowel syndrome, with 30 million potential patients in the U.S., and the pricing decision positions Biomerica for expanded market access and revenue growth in 2026.